Takeda Yasuo, Ikeda Ryuji, Kondo Tomoko
Department of Clinical Pharmacy and Pharmacology, Kagoshima University Hospital.
Yakugaku Zasshi. 2016;136(4):573-7. doi: 10.1248/yakushi.15-00264-2.
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been recognized as metabolic disorders characterized by fatty accumulation in the liver without alcohol consumption. The diseases can cause metabolic syndromes, consisting of obesity, diabetes mellitus (DM), dyslipidemia and hypertension. For the treatment of NAFLD/NASH, losing weight by exercise or diet remains the standard treatment, because no effective pharmacological therapy has yet been developed for NAFLD/NASH. Two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), stimulate glucose-mediated insulin production in pancreatic β cells. Incretin has also been reported to have various extra-pancreatic effects, including the regulation of hepatic glucose production, appetite and satiety, as well as the stimulation of afferent sensory nerves. Therefore, incretin may have potential as a novel therapeutic agent for NAFLD/NASH.
非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）已被确认为代谢紊乱，其特征是在不饮酒的情况下肝脏中脂肪堆积。这些疾病可导致代谢综合征，包括肥胖、糖尿病（DM）、血脂异常和高血压。对于NAFLD/NASH的治疗，通过运动或饮食减肥仍然是标准治疗方法，因为尚未开发出针对NAFLD/NASH的有效药物治疗方法。两种肠促胰岛素激素，胰高血糖素样肽-1（GLP-1）和葡萄糖依赖性促胰岛素多肽（GIP），刺激胰腺β细胞中葡萄糖介导的胰岛素分泌。据报道，肠促胰岛素还具有多种胰腺外作用，包括调节肝葡萄糖生成、食欲和饱腹感，以及刺激传入感觉神经。因此，肠促胰岛素可能具有作为NAFLD/NASH新型治疗药物的潜力。
